SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Dec 24, 2009
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The SwissNET study is focused on understanding a rare type of cancer known as gastroentero-pancreatic neuroendocrine tumors (GEP-NETs), which can develop in the gastrointestinal tract and pancreas. These tumors can be difficult to treat, and there is still a lot we don’t know about them. The study aims to gather information from patients diagnosed with GEP-NETs in Switzerland to learn more about the different types of these tumors, the treatments used, and how well patients are doing.
To participate in this study, individuals need to have been diagnosed with a neuroendocrine tumor in Switzerland, regardless of where it started in the body, and they must provide informed consent. As part of the trial, patients will have their medical data collected and stored anonymously in a secure database. This information will help researchers better understand GEP-NETs, which may lead to improved treatment options in the future. If you or someone you know is affected by this condition, participating in the SwissNET registry could contribute to important advancements in care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Neuroendocrine tumor irrespective of primary tumor location
- • Diagnosis in Switzerland
- • Given informed consent
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
St. Gallen, , Switzerland
Zürich, , Switzerland
Aarau, , Switzerland
Geneva, , Switzerland
Olten, , Switzerland
Schlieren, , Switzerland
Liestal, , Switzerland
Bellinzona, , Switzerland
Zürich, , Switzerland
Luzern, , Switzerland
Aarberg, , Switzerland
Affoltern Am Albis, , Switzerland
Altdorf, , Switzerland
Basel, , Switzerland
Bern, , Switzerland
Bern, , Switzerland
Bern, , Switzerland
Biel, , Switzerland
Bruderholz, , Switzerland
Burgdorf, , Switzerland
Churwalden, , Switzerland
Chur, , Switzerland
Delémont, , Switzerland
Dornach, , Switzerland
Einsiedeln, , Switzerland
Grabs, , Switzerland
Horgen, , Switzerland
Horgen, , Switzerland
Interlaken, , Switzerland
Lachen, , Switzerland
Langenthal, , Switzerland
Laufen, , Switzerland
Lausanne, , Switzerland
Luzern, , Switzerland
Luzern, , Switzerland
Männedorf, , Switzerland
Münsterlingen, , Switzerland
Rheinfelden, , Switzerland
Sarnen, , Switzerland
Schwyz, , Switzerland
Seuzach, , Switzerland
Sion, , Switzerland
Solothurn, , Switzerland
Stans, , Switzerland
Thun, , Switzerland
Uster, , Switzerland
Visp, , Switzerland
Winterthur, , Switzerland
Wolhusen, , Switzerland
Zollikerberg, , Switzerland
Zug, , Switzerland
Zweisimmen, , Switzerland
Zürich, , Switzerland
Zürich, , Switzerland
Patients applied
Trial Officials
Aurel Perren, MD
Study Director
Institute of Pathology, University of Bern, Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials